Author Archives: Iqra Mumal, MSc

Boehringer Ingelheim Acquires Enleofen’s Anti-IL-11 Therapeutic Platform for Fibrotic Diseases

Boehringer Ingelheim has acquired the worldwide exclusive rights to Enleofen‘s interleukin-11 (IL-11) platform, designed for the treatment of fibrotic diseases such as pulmonary fibrosis. This newly established partnership brings together Boehringer Ingelheim’s expertise and substantial pipeline in fibrotic diseases, and Enleofen’s knowledge of IL-11 biology. Enleofen…